3SBio (SEHK:1530) Valuation Check After Strong 2025 Sales And Earnings Growth

3SBio (SEHK:1530) just released full year 2025 results, reporting sales of CNY 17,695.75 million and net income of CNY 8,482.16 million, drawing fresh attention to the stock’s recent move.

See our latest analysis for 3SBio.

The earnings release follows a board meeting earlier in March that highlighted these results and a potential final dividend. The strong full year figures appear to align with fresh interest in the stock, with a 7 day share price return of 13.25% and a 1 year total shareholder return of 104.64% pointing to momentum that has built meaningfully over time.

If this kind of performance has you thinking about what else is moving in healthcare, it could be worth scanning 120 healthcare AI stocks as a way to surface more ideas beyond 3SBio.

After such strong reported earnings and a powerful 1 year total return, the key question is whether 3SBio’s current price still reflects a discount, or if the market is already pricing in future growth and leaving little on the table.

Price to earnings of 22.7x: Is it justified?

On a P/E of 22.7x, 3SBio is priced below both its peer average of 67x and the Asian biotechs industry average of 35.6x, even after a strong share price run.

The P/E ratio tells you how much investors are paying for each unit of current earnings, which is especially watched in profitable healthcare names. For 3SBio, earnings grew 42.2% over the past year and have grown 13.4% per year over the past 5 years, and those figures help explain why the market is willing to pay more than the estimated fair P/E of 17.9x, while still keeping the stock below many peers.

Compared to the estimated fair P/E of 17.9x, the current 22.7x suggests investors are paying a premium to where the SWS fair ratio model indicates the multiple could settle. Yet against the Asian biotechs average of 35.6x and a peer average of 67x, the same 22.7x looks restrained, which hints that the market is not pricing 3SBio as aggressively as many other names in the space.

Explore the SWS fair ratio for 3SBio

Result: Price-to-earnings of 22.7x (ABOUT RIGHT)

However, recent annual revenue and net income declines, plus mostly China based sales, leave the story exposed to earnings pressure or regulatory changes.

Find out about the key risks to this 3SBio narrative.

Another view on value

While the current 22.7x P/E looks roughly in line with the story so far, the SWS DCF model presents a different view. It shows an estimated future cash flow value of HK$55.07 compared with the HK$24.28 share price, suggesting that 3SBio trades at a steep discount on that measure.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 3SBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 244 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and sentiment, it makes sense to look at the full picture yourself and decide quickly where you stand, including weighing 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If 3SBio has caught your attention, do not stop there. Expanding your watchlist with fresh ideas can help you spot opportunities before the crowd notices.

• Target quality at a discount by scanning 244 high quality undervalued stocks that combine appealing fundamentals with potential upside.
• Prioritize resilience by checking 263 resilient stocks with low risk scores if you want companies with steadier profiles.
• Hunt for potential future leaders using the screener containing 598 high quality undiscovered gems before they become widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com